Recurrence and Associated Factors in Cured Patients with Newly Diagnosed Smear-positive Pulmonary Tuberculosis:a Follow-up Study
Department of Respiratory Medicine,the Third People's Hospital of Pingxiang City,Pingxiang 337055,China
*Corresponding author:LI Ying,Associate chief physician;E-mail:y8951354@163.com
LI Ying,WANG Zukang,WEI Youliang, et al. Recurrence and Associated Factors in Cured Patients with Newly Diagnosed Smear-positive Pulmonary Tuberculosis:a Follow-up Study [J]. Chinese General Practice, 2021, 24(14): 1785-1789. DOI: 10.12114/j.issn.1007-9572.2021.00.510.
李鹰,王祖康,魏尤良等. 初治涂阳肺结核患者治愈后的随访观察及复发情况的影响因素分析[J]. 中国全科医学, 2021, 24(14): 1785-1789. DOI: 10.12114/j.issn.1007-9572.2021.00.510.
[1]孔雯,刘巧,宋红焕,等.初始复治涂阳肺结核病例短程化疗方案的临床疗效和安全性[J].江苏预防医学,2017,28(6):637-639.DOI:10.13668/j.issn.1006-9070.2017.06.10.
KONG W,LIU Q,SONG H H,et al.Clinical efficacy and safety of short course chemotherapy for initial retreatment smear positive pulmonary tuberculosis[J].Jiangsu Journal of Preventive Medicine,2017,28(6):637-639.DOI:10.13668/j.issn.1006-9070.2017.06.10.
[2]李波,曹文利,裴宁,等.初治涂阳老年人肺结核化疗新方案的疗效评价[J].中华老年医学杂志,2019,38(3):237-241.DOI:10.3760/cma.j.issn.0254-9026.2019.03.004.
LI B,CAO W L,PEI N,et al.Evaluation of effectiveness on a new chemotherapy regimen for the initial treatment of smear-positive tuberculosis in the elderly [J].Chinese Journal of Geriatrics,2019,38(3):237-241.DOI:10.3760/cma.j.issn.0254-9026.2019.03.004.
[3]应潜,黄文辉,陈小菁,等.282例肺结核患者结核分枝杆菌耐药基线调查及耐多药结核病影响因素分析[J].现代预防医学,2018,45(19):3597-3600,3604.
YING Q,HUANG W H,CHEN X J,et al.Baseline study on drug resistance of tuberculosis of 282 patients and influencing factor of multi-drug resistance tuberculosis[J].Mod Prev Med,2018,45(19):3597-3600,3604.
[4]潘虹,李腾根,周银古,等.2014—2017年新余市结核病耐药特征及影响因素分析[J].现代预防医学,2018,45(4):725-728.
PAN H,LI T G,ZHOU Y G,et al.Analysis on the characteristics and influence factors of drug resistance tuberculosis in Xinyu City from 2014 to 2017[J].Mod Prev Med,2018,45(4):725-728.
[5]黎永华,李朝勇,黄隆.三亚市肺结核患者治愈后复发危险因素调查分析[J].中华疾病控制杂志,2017,21(1):102-104.DOI:10.16462/j.cnki.zhjbkz.2017.01.024.
LI Y H,LI Z Y,HUANG L.Risk factors investigation analysis on relapse after curing pulmonary tuberculosis patients in Sanya City[J].Chin J Dis Control Prev,2017,21(1):102-104.DOI:10.16462/j.cnki.zhjbkz.2017.01.024.
[6]陈瑜晖,钟球,周琳,等.不同方案治疗复治肺结核的疗效评价[J].广东医学,2017,38(15):2355-2358.DOI:10.3969/j.issn.1001-9448.2017.15.028.http://d.wanfangdata.com.cn/periodical/gdyx201715028.
[7]邵妍,温华.初治时长对新发涂阳肺结核患者复发因素分析[J].热带医学杂志,2018,18(2):195-198.DOI:10.3969/j.issn.1672-3619.2018.02.016.
SHAO Y,WEN H.Analysis of recurrent factors in newly diagnosed smear positive pulmonary tuberculosis patients[J].J Trop Med,2018,18(2):195-198.DOI:10.3969/j.issn.1672-3619.2018.02.016.
[8]侯锡花.1982年全国结核病防治学术会议[J].医学研究通讯,1982,11(8):11-13.http://www.cnki.com.cn/Article/CJFDTotal-YXYZ198208007.htm.
[9]许卫国,高瞻,范本达.短程化疗结束后痰菌阴性肺结核患者复发情况随访观察[J].中华结核和呼吸杂志,2003,6(2):74-76.DOI:10.3760/j:issn:1001-0939.2003.02.004.
XU W G,GAO Z,FAN B D.Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy[J].Chinese Journal of Tuberculosis and Respiratory Diseases,2003,26(2):74-76.DOI:10.3760/j:issn:1001-0939.2003.02.004.
[10]史克咏,陈三钧,傅茂英,等.结核抗体,痰涂片及PPD试验对肺结核诊断价值的比较研究[J].医学临床研究,2010,27(8):1551-1552.DOI:10.3969/j.issn.1671-7171.2010.08.064.http://d.wanfangdata.com.cn/periodical/hnyx201008064.
[11]中国科协学会学术部.结核病新型诊断技术的应用[M].北京:中国科学技术出版社,2015.
[12]李文志.初治涂阳肺结核5个月化疗疗效观察及3年随访报告[J].临床荟萃,1999,14(4):145.DOI:10.3969/j.issn.1004-583X.1999.04.001.http://d.wanfangdata.com.cn/periodical/lchc199904001.
[13]中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.DOI:10.3760/cma.j.issn.1001?0939.2019.10.006.http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zhjhhhx201910007.
[14]李琦,李亮.耐多药或利福平耐药结核病长程化疗方案与短程化疗方案的利与弊[J].中华结核和呼吸杂志,2019,42(5):333-338.DOI:10.3760/cma.j.issn.1001-0939.2019.05.005.http://d.wanfangdata.com.cn/periodical/zhjhhhx201905005.
[15]李君,单志力,朱小梅,等.结核分枝杆菌对一线抗结核药物的耐药性分析[J].中华医院感染学杂志,2018,28(13):1925-1928.DOI:10.11816/cn.ni.2018-171962.
LI J,SHAN Z L,ZHU X M,et al.Drug resistance of Mycobacterium tuberculosis strains to first-line anti-tuberculosis drugs[J].Chinese Journal of Nosocomiology,2018,28(13):1925-1928.DOI:10.11816/cn.ni.2018-171962.
[16]金玲玲,施伎蝉,蒋贤高,等.短程化疗方案在初次复发涂阳肺结核中的效果评价[J].中华全科医学,2019,17(9):1508-1511.DOI:10.16766/j.cnki.issn.1674-4152.000982.
JIN L L,SHI J C,JIANG X G,et al.Evaluation of short-term chemotherapy regimen in the first recurrence pulmonary tuberculosis[J].Chinese Journal of General Practice,2019,17(9):1508-1511.DOI:10.16766/j.cnki.issn.1674-4152.000982.
[17]周洁,崔爱东,周千祥.高浓度异烟肼利福平治疗低度耐多药肺结核的临床研究[J].内蒙古医学杂志,2011,43(11):1291-1293.DOI:10.16096/j.cnki.nmgyxzz.2011.11.017.
ZHOU J,CUI A D,ZHOU Q X.High concentration and large dose isoniazid and rifampicin perfusion on treatment of multi-drug resistance pulmonary tuberculosis[J].Inner Mongolia Medical Journal,2011,43(11):1291-1293.DOI:10.16096/j.cnki.nmgyxzz.2011.11.017.
[18]冼翠平,陈小华,许卓卫,等.影响初治菌阳肺结核病人强化期痰菌阴转因素研究[J].中国防痨杂志,2008,30(1):7-10.DOI:10.3969/j.issn.1000-6621.2008.01.003.
XIAN C P,CHEN X H,XU Z W,et al.Study on the reason of affecting the smear negative result at the end of 2nd month of treatment of new smear positive pulmonary tuberculosis patients[J].Chinese Journal of Antituberculosis,2008,30(1):7-10.DOI:10.3969/j.issn.1000-6621.2008.01.003.
[19]申恩瑞,彭惠,陈青,等.停用吡嗪酰胺对初治结核病患者血尿酸水平的影响[J].广东医学,2018,39(24):3701-3705.DOI:10.3969/j.issn.1001-9448.2018.24.027.http://d.wanfangdata.com.cn/periodical/gdyx201824027.
[20]吴碧彤,邝浩斌,刘志辉,等.标准耐多药结核病化疗方案中是否对吡嗪酰胺耐药的疗效对比研究[J].中国防痨杂志,2019,41(4):447-451.DOI:10.3969/j.issn.1000-6621.2019.04.015.
[21]吴碧彤,陶岚,黎燕琼,等.首次复治耐多药肺结核采用短程与标准化疗方案的疗效分析[J].中国防痨杂志,2018,40(6):639-643.DOI:10.3969/j.issn.1000-6621.2018.06.017.
[22]贾意国,王美花,李怀臣,等.2006—2015年济南市肺结核流行特征分析[J].山东医药,2018,58(37):71-73.DOI:10.3969/j.issn.1002-266X.2018.37.020.
[23]沈艳,姜伟,彭红,等.2011—2015年张家港市痰培养阳性结核病的耐药分析[J].现代预防医学,2017,44(3):537-541.
SHEN Y,JIANG W,PENG H,et al.Drug resistant tuberculosis in Zhangjiagang,2011—2015[J].Modern Preventive Medicine,2017,44(3):537-541.